Search results for "Human papillomavirus vaccine"

showing 3 items of 3 documents

Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27–45 years of age compared to women 16–26 years of age: An open-lab…

2021

Abstract: Background: Efficacy of the nine-valent human papillomavirus (9vHPV; HPV types 6/11/16/18/31/33/45/52/58) vaccine was demonstrated in a phase 3 study in women 16 & ndash;26 years of age. We present a phase 3 immunogenicity and safety study of the 9vHPV vaccine in women 27 & ndash;45 versus 16 & ndash;26 years of age. Methods: This international, open-label study (NCT03158220) was conducted in women 16 & ndash;45 years of age. Participants (16 & ndash;26 years, n = 570 and 27 & ndash;45 years, n = 642) received a three-dose 9vHPV vaccination regimen (day 1, month 2, month 6). Month 7 geometric mean titers (GMTs) and seroconversion percentages to anti-HPV 6/11/16/18/31/33/45/52/58 w…

AdultHuman papillomavirusmedicine.medical_specialtyAdolescentAntibodies ViralYoung Adult03 medical and health sciencesNine-valent human papillomavirus vaccineImmunogenicity Vaccine0302 clinical medicine030225 pediatricsInternal medicinemedicineHumansPapillomavirus Vaccines030212 general & internal medicineSeroconversionHPV prophylaxisAdverse effectAgedCervical cancerHuman papillomavirus 16Human papillomavirus 18General VeterinaryGeneral Immunology and Microbiologybusiness.industryPapillomavirus InfectionsAdult vaccinationPublic Health Environmental and Occupational Healthmedicine.diseaseVaccine efficacyConfidence interval3. Good healthVaccinationClinical trialPrecancerRegimenInfectious DiseasesCervical cancerMolecular MedicineFemaleHuman medicinebusinessVaccine
researchProduct

Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine administered according to an alternative dosing schedule compared wit…

2011

BACKGROUND: The human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine is immunogenic, has a clinically acceptable safety profile, and prevents incident and persistent HPV-16/18 infection and cervical precancerous lesions. This study (NCT00552279) evaluated the vaccine when administered according to an alternative dosing schedule (0-1-12 months) compared with the standard dosing schedule (0-1-6 months). METHODS: The study was of randomized open design and was conducted at multiple centers in Europe. Healthy women aged 15 to 25 years were randomized (1:1) to receive HPV-16/18 vaccine according to the standard schedule at months 0, 1, and 6 (n = 401) or an alternative schedule at months 0, …

AdultMicrobiology (medical)medicine.medical_specialtyScheduleAdolescentImmunization SecondaryEnzyme-Linked Immunosorbent AssayAntibodies Virallaw.inventionYoung AdultAdjuvants ImmunologicRandomized controlled triallawInternal medicinemedicineHumansPapillomavirus VaccinesDosingHuman papillomavirusYoung adultbusiness.industryImmunogenicityhuman papillomavirus human papillomavirus vaccines adolescent immunology alternative dosing scheduleVaccinationvirus diseasesSettore MED/40 - Ginecologia E Ostetriciafemale genital diseases and pregnancy complicationsEuropeSafety profileInfectious DiseasesImmunizationPediatrics Perinatology and Child HealthImmunologyFemalebusiness
researchProduct

[Adverse reactions to human papillomavirus vaccine in the Valencian Community (2007-2011)].

2014

Introduction: In 2009, two cases of seizures in adolescents following quadrivalent human papillomavirus vaccine (qHPV) administration generated important media attention, and adversely affected public trust in this vaccine. Our objectives were to describe suspected adverse reactions (SARs) reported to the Pharmacovigilance Centre in the Valencian Community (PCVC) after administration of HPV vaccine, and to compare reporting rates of syncope and seizures following this vaccine with those of other vaccines administered to girls aged 13–15 years. Materials and methods: Descriptive study of SARs reported following administration of this vaccine to the PCVC between 2007 and 2011. Results: The cl…

medicine.medical_specialtyPediatricsHuman papillomavirusTime FactorsAdolescentVirus del papiloma humanoVaccines AdministeredHuman papillomavirus vaccinePediatricsRJ1-570Valencian communitySyncopeReporting ratePharmacovigilanceHuman Papillomavirus Recombinant Vaccine Quadrivalent Types 6 11 16 18SeizuresManagement of Technology and InnovationPharmacovigilanceMedicineHumansRetrospective StudiesbiologyVacunabusiness.industryReacción adversaSyncope (genus)PharmacovigitanceTasa de notificaciónbiology.organism_classificationSurgeryVaccinationFarmacovigilanciaSpainFemalebusinessAdverse reactionsVaccineAnales de pediatria (Barcelona, Spain : 2003)
researchProduct